Date: 2015-03-18
Type of information: Treatment of the first patient
phase: 2
Announcement: treatment of the first patient
Company: Cell Medica (UK)
Product: CMD-003 - autologous Epstein-Barr virus specific T-cells
Action
mechanism: cell therapy/cell immunotherapy. This novel cellular therapy product comprises T-cells targeted at malignant cells that express the oncogenic Epstein Barr virus (EBV). The expression of EBV antigens by tumor cells thus provides the opportunity to use the patient’s own immune cells to target and kill the cancer. CMD-003 is produced from the patient’s own T cells which are harvested from a blood sample and sent to Cell Medica’s manufacturing site for activation and expansion through a proprietary procedure that has been developed for commercial-scale use.
Disease: aggressive extranodal NK/T cell lymphoma (ENKTCL)
Therapeutic area: Cancer - Oncology
Country:
Trial
details: The CITADEL trial is a phase 2 single arm study to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma (ENKTCL). (NCT01948180)
Latest
news: * On March 18, 2015, Imperial Innovations Group announced that its portfolio company Cell Medica has announced the treatment of the first patient in its CITADEL Phase II trial. This clinical study is investigating the safety and efficacy of CMD-003 for the treatment of aggressive extranodal NK/T cell lymphoma (ENKTCL) in patients whose treatment with other therapies has proved unsuccessful. The patient was treated at Dana-Farber Cancer Center in Boston, Massachusetts. The CITADEL Trial will investigate whether CMD-003 is safe and effective as a potential therapy for patients who have failed conventional treatment of advanced extranodal NK/T cell lymphoma. The trial will include NK/T cell lymphoma patients recruited at 24 centres in five countries as part of clinical development programme aimed at regulatory approval in the USA, Europe and Korea.
